{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:40:34Z","timestamp":1790138434842,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:00:00Z","timestamp":1570579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Self funded"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>During the initial scale up of ART in sub-Saharan Africa, prescribed regimens included drugs with high potential for toxicity (particularly stavudine). More recently a growing number of patients requires second line treatment due to treatment failure, especially following the expansion of viral load testing. We aim to determine the reasons and risk factors for modification of first line ART across the years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included patients started on standard first line ART (2NRTI\u2009+\u20091 NNRTI) between 2005 and 2016 at the Infectious Diseases Institute, Kampala, Uganda. We described the reasons for treatment modification categorized in (1) toxicity (2) treatment failure (3) other reason (new TB treatment, new pregnancy). We used Cox proportional hazard to identify factors associated with treatment modification due to toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 14,261 patients; 9114 (63.9%), were female, the median age was 34\u00a0years (IQR: 29\u201340), 60.8% were in WHO stage 3 and 4. The median BMI and CD4 count were 21.9 (IQR: 19.6\u201324.8) and 188 cell\/\u00b5L (IQR: 65\u2013353) respectively; 27.5% were started on stavudine, 46% on zidovudine, and 26.5% on a tenofovir containing regimens. We observed 6248 ART modifications in 4868\/14,261 patients (34.1%); 1615 were due to toxicity, 1077 to treatment failure, 1330 to contraindications, and 1860 patients following WHO recommendation of phasing out stavudine and substituting with another NRTI. Modification for drug toxicity declined rapidly after the phase out of stavudine (2008), while switches to second line regimes increased after the implementation of viral load monitoring (2015). Patients with normal BMI compared to underweight, (HR: 0.79, CI 0.69\u20130.91), with CD4 counts 200\u2013350 cells\/\u00b5L compared to\u2009&lt;\u2009200 cells\/\u00b5L (HR: 0.81\u2212 CI 0.71\u20130.93), and started on zidovudine (HR: 0.51 CI 0.44\u20130.59) and tenofovir (HR: 0.16, CI 0.14\u20130.22) compared to stavudine were less likely to have ART modification due to toxicity. Older patients (HR: 1.14 per 5-year increase CI 1.11\u20131.18), those in WHO stage 3 and 4 (HR: 1.19, CI 1.06\u20131.34) were more likely to have ART modification due to toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Toxicity as reason for drugs substitution decreased over time mirroring the phase out of stavudine, while viral load expansion identified more patients in need of second line treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-019-0246-y","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T14:27:26Z","timestamp":1570631246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reasons for first line ART modification over the years during the ART scale up in Uganda"],"prefix":"10.1186","volume":"16","author":[{"given":"B.","family":"Castelnuovo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mubiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kalule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kiragga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"246_CR1","unstructured":"World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003. Accessed Jan 2011."},{"issue":"2","key":"246_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191\u2013201.","journal-title":"JAMA"},{"issue":"5","key":"246_CR3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/135965350701200508","volume":"12","author":"A Boulle","year":"2007","unstructured":"Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3\u00a0years of antiretroviral therapy in a large South African cohort. Antivir Ther. 2007;12(5):753\u201360.","journal-title":"Antivir Ther."},{"issue":"1","key":"246_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/QAI.0b013e3181f5bd03","volume":"56","author":"B Castelnuovo","year":"2011","unstructured":"Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr. 2011;56(1):59\u201363.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"246_CR5","doi-asserted-by":"publisher","first-page":"e93106","DOI":"10.1371\/journal.pone.0093106","volume":"9","author":"S Inzaule","year":"2014","unstructured":"Inzaule S, Otieno J, Kalyango J, Nafisa L, Kabugo C, Nalusiba J, et al. Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS ONE. 2014;9(4):e93106.","journal-title":"PLoS ONE"},{"issue":"6","key":"246_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1086\/605500","volume":"49","author":"B Castelnuovo","year":"2009","unstructured":"Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3\u00a0years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis. 2009;49(6):965\u201372.","journal-title":"Clin Infect Dis"},{"key":"246_CR7","unstructured":"Uhanda Ministry of Health. National Antiretroviral treatment and Care Guidelines for Adults and Children. 2nd edition 2008. Accessed Aug 2011."},{"issue":"1","key":"246_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/QAD.0000000000001307","volume":"31","author":"AT Brennan","year":"2017","unstructured":"Brennan AT, Davies MA, Bor J, Wandeler G, Stinson K, Wood R, et al. Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa? AIDS. 2017;31(1):147\u201357.","journal-title":"AIDS."},{"key":"246_CR9","unstructured":"World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendation for a public health approach. 2010. Accessed Jan 2011."},{"issue":"1","key":"246_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/QAI.0b013e3181c6c65c","volume":"54","author":"BH Chi","year":"2010","unstructured":"Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010;54(1):63\u201370.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"246_CR11","doi-asserted-by":"publisher","first-page":"e64459","DOI":"10.1371\/journal.pone.0064459","volume":"8","author":"K Velen","year":"2013","unstructured":"Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS ONE. 2013;8(5):e64459.","journal-title":"PLoS ONE"},{"issue":"3","key":"246_CR12","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1097\/QAI.0b013e3182097505","volume":"56","author":"H Bygrave","year":"2011","unstructured":"Bygrave H, Ford N, van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, et al. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr. 2011;56(3):e75\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"246_CR13","doi-asserted-by":"publisher","first-page":"e63596","DOI":"10.1371\/journal.pone.0063596","volume":"8","author":"C Njuguna","year":"2013","unstructured":"Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS ONE. 2013;8(5):e63596.","journal-title":"PLoS ONE"},{"key":"246_CR14","unstructured":"World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants\u2014Programmatic update. WHO: Geneva; 2012. http:\/\/apps.who.int\/iris\/bitstream\/10665\/70892\/2\/WHO_HIV_2012.6_eng.pdf . Accessed June 2017."},{"issue":"7","key":"246_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","volume":"9","author":"RK Gupta","year":"2009","unstructured":"Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9(7):409\u201317.","journal-title":"Lancet Infect Dis."},{"issue":"10","key":"246_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","volume":"11","author":"RL Hamers","year":"2011","unstructured":"Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11(10):750\u20139.","journal-title":"Lancet Infect Dis."},{"key":"246_CR17","unstructured":"World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006. Accessed Jan 2011."},{"issue":"6","key":"246_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/QAD.0b013e3283262a78","volume":"23","author":"SJ Reynolds","year":"2009","unstructured":"Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23(6):697\u2013700.","journal-title":"AIDS."},{"issue":"10","key":"246_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/QAD.0b013e32832cbd43","volume":"23","author":"Barbara Castelnuovo","year":"2009","unstructured":"Castelnuovo B, Kiragga A, Schaefer P, Kambugu A, Manabe Y. High rate of misclassification of treatment failure based on WHO immunological criteria. AIDS. 2009;23(10):1295-6; author reply 6.","journal-title":"AIDS"},{"issue":"1","key":"246_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/QAI.0b013e318227fc34","volume":"58","author":"KC Sigaloff","year":"2011","unstructured":"Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58(1):23\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"246_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1472-698X-12-11","volume":"12","author":"S Nwaka","year":"2012","unstructured":"Nwaka S, Ochem A, Besson D, Ramirez B, Fakorede F, Botros S, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. BMC Int Health Human Rights. 2012;12:11.","journal-title":"BMC Int Health Human Rights."},{"issue":"5","key":"246_CR22","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1097\/QAI.0000000000000820","volume":"70","author":"B Castelnuovo","year":"2015","unstructured":"Castelnuovo B, Nsumba M, Musomba R, Kaimal A, Lwanga I, Kambugu A, et al. Strengthening the \u201cViral failure pathway\u201d: clinical decision and outcomes of patients with confirmed viral failure in a large HIV Care Clinic in Uganda. J Acquir Immune Defic Syndr. 2015;70(5):e174\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"246_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1472-6963-9-192","volume":"9","author":"JB Babigumira","year":"2009","unstructured":"Babigumira JB, Castelnuovo B, Lamorde M, Kambugu A, Stergachis A, Easterbrook P, et al. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res. 2009;9:192.","journal-title":"BMC Health Serv Res."},{"issue":"12","key":"246_CR24","doi-asserted-by":"publisher","first-page":"e51631","DOI":"10.1371\/journal.pone.0051631","volume":"7","author":"B Castelnuovo","year":"2012","unstructured":"Castelnuovo B, Kiragga A, Afayo V, Ncube M, Orama R, Magero S, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa. PLoS ONE. 2012;7(12):e51631.","journal-title":"PLoS ONE"},{"issue":"4","key":"246_CR25","doi-asserted-by":"publisher","first-page":"514","DOI":"10.5588\/ijtld.18.0306","volume":"23","author":"J Musaazi","year":"2019","unstructured":"Musaazi J, Sekaggya-Wiltshire C, Kiragga AN, Kalule I, Reynolds SJ, Manabe YC, et al. Sustained positive impact on tuberculosis treatment outcomes of TB-HIV integrated care in Uganda. Int J Tuberc Lung Dis. 2019;23(4):514\u201321.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"18","key":"246_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","volume":"360","author":"MM Kitahata","year":"2009","unstructured":"Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"246_CR27","doi-asserted-by":"publisher","first-page":"e015490","DOI":"10.1136\/bmjopen-2016-015490","volume":"8","author":"B Castelnuovo","year":"2018","unstructured":"Castelnuovo B, Mubiru F, Kiragga AN, Musomba R, Mbabazi O, Gonza P, et al. Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10\u00a0years of ART-experienced patients in Uganda. BMJ Open. 2018;8(2):e015490.","journal-title":"BMJ Open"},{"key":"246_CR28","unstructured":"Castelnuovo B, Mubiru F, Kiragga A, Reynolds SJ. Compliance to guidelines for vira load testing in resource limited settings. Conference on Retroviruses and Opportunistic Infections (CROI) Boston 4\u20137 March 2019."},{"issue":"1","key":"246_CR29","doi-asserted-by":"publisher","first-page":"21803","DOI":"10.7448\/IAS.20.1.21803","volume":"20","author":"ND Labhardt","year":"2017","unstructured":"Labhardt ND, Ringera I, Lejone TI, Cheleboi M, Wagner S, Muhairwe J, et al. When patients fail UNAIDS\u2019 last 90\u2014the \u201cfailure cascade\u201d beyond 90\u201390\u201390 in rural Lesotho, Southern Africa: a prospective cohort study. J Int AIDS Soc. 2017;20(1):21803.","journal-title":"J Int AIDS Soc."},{"issue":"1","key":"246_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1186\/s13104-017-2948-3","volume":"10","author":"CA Dimala","year":"2017","unstructured":"Dimala CA, Bechem NN, Aroke D, Kadia BM. Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV\/AIDS patients at a major referral centre in South-west Cameroon. BMC Res Notes. 2017;10(1):623.","journal-title":"BMC Res Notes."},{"issue":"10","key":"246_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/j.1365-3156.2009.02338.x","volume":"14","author":"O Keiser","year":"2009","unstructured":"Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health. 2009;14(10):1220\u20135.","journal-title":"Trop Med Int Health."},{"issue":"12","key":"246_CR32","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1093\/cid\/cir729","volume":"53","author":"HE Rawizza","year":"2011","unstructured":"Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankale JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283\u201390.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"246_CR33","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/QAD.0b013e32832e05b2","volume":"23","author":"O Keiser","year":"2009","unstructured":"Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867\u201374.","journal-title":"AIDS."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0246-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-019-0246-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0246-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T08:13:30Z","timestamp":1664612010000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-019-0246-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1186\/s12981-019-0246-y","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,9]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol \u201cAnalysis of routinely collected data to evaluate, monitor, and assess outcomes at the Adult Infectious Diseases Clinic (AIDC), Kampala, Uganda\u201d was reviewed and approved by the Makerere University Faculty of Medicine Research and Ethics Committee (Approval Number: 120-2009) and the Uganda National Council for Science and Technology (Approval Number: HS 683). The investigators obtained verbal or written consent waiver, but all patients information is analyzed after stripping it of unique personal identifiers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}